Autologous hematopoietic stem cell transplantation (aHSCT) is the only treatment for refractory autoimmune diseases capable of inducing long-term, drug-free and asymptomatic remission. Over the past two decades, aHSCT has been used to treat inflammatory autoimmune disease of the CNS. Patients with relapsing-remitting multiple sclerosis benefit from aHSCT treatment. However, a certain percentage of patients still experience recurrence 3 or 5 years after transplantation. Therefore, exploration of conditioning regimens will drive therapeutic advances in aHSCT in autoimmune diseases of the CNS.
Age 18-60 years;
Diagnosed multiple sclerosis with relapses or progression and sustained accumulated impairment by a neurologist expert in the field;
EDSS score of 3-6 (including 3 and 6);
EDSS cerebellar functional score ≥ 3 or EDSS pyramidal functional score ≥3；
Patients with evidence of myelodysplasia or other non-autoimmune cytopenia;
Patients having received a cytotoxic agent within one month of enrolling in this study;
Patient with any active or chronic infection (herpes simplex virus, varicella-zoster virus, cytomegalovirus, EB virus, human immunodeficiency virus, hepatitis virus, syphilis, etc.);
Patients having received a cytotoxic agent within one month of enrolling in this study;